NASDAQ: SXTCChina Sxt Pharmaceuticals Inc Stock
$1.06+0.04 (+3.92%)
Updated Apr 22, 2024
SXTC Price
$1.06
Fair Value Price
N/A
Market Cap
$771.52k
52 Week Low
$0.94
52 Week High
$9.38
P/E
-0.04x
P/B
0.15x
P/S
51.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$29.92k
Earnings
-$14.14M
Gross Margin
3,703.2%
Operating Margin
-45,814.74%
Profit Margin
-47,248.6%
Debt to Equity
1.87
Operating Cash Flow
-$111k
Beta
0.98
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SXTC Overview
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SXTC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SXTC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SXTC is good value based on its book value relative to its share price (0.15x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.04x)
P/B vs Industry Valuation
SXTC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SXTC due diligence checks available for Premium users.
Be the first to know about important SXTC news, forecast changes, insider trades & much more!
SXTC News
Valuation
SXTC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.04x
Industry
46.47x
Market
41x
SXTC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.15x
Industry
2.04x
SXTC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SXTC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
SXTC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SXTC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.6M
Liabilities
$9.5M
Debt to equity
1.87
SXTC's short-term assets ($13.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SXTC's short-term assets ($13.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SXTC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SXTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
SXTC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SXTC vs Pharmaceutical Stocks
China Sxt Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.